Keywords
HBV infection
Hepatocellular carcinoma
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To elucidate how therapies with interferons and nucleotide analogues in patients infected with hepatitis B virus cause reversal of liver cirrhosis and hepatocarcinoma. Literature review: Entecavir has demonstrated virological and biochemical benefits, reducing the incidence of drug-resistant mutations, and being associated with a lower risk of death. Interferons (IFNs) have been used to treat chronic hepatitis B/C, IFNs induce APOBEC3G expression with activation of STAT3 inhibiting HBV, complexes of these IFNs activate the Janus-activated kinase signal transducer (JAK) and the transcription pathway activator (STAT), leading to the expression of IFN-stimulated genes (ISGs). Studies with tenofovir for hepatitis B suggest that it reverses hepatic fibrosis, tenofovir is hydrolysed by intestinal and plasma esterases, and is metabolized mainly intracellularly by cathepsin A. Final considerations: IFNs activate immune cells responsible for the antiviral response, entecavir acts as the HBV DNA strand terminator, and tenofovir is associated with reversal of liver fibrosis and restoration of kidney function.
References
CAMPOS-VALDEZ M, et al. Molecular Mechanisms during Hepatitis B Infection and the Effects of the Virus Variability. Viruses, 2021; 13(6): 1167.
CHEN Y, TIAN Z. HBV-Induced Immune Imbalance in the Development of HCC. Frontiers in Immunology, 2019; 10:2048.
CHISARI F, et al. Pathogenesis of hepatitis B virus infection. Pathologie Biologie, 2010; 58(4):258-266.
CLERCQ ED, et al. Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections. Viruses, 2010; 6(2):1279-1305.
FEIG JL, et al. The antiviral drug tenofovir, an inhibitor of Pannexin-1-mediated ATP release, prevents liver and skin fibrosis by downregulating levels in the liver and skin. Plos One, 2017; 12(11):e0188135.
HAMLIN AN, et al. Genetic variations of kinases and activation of nucleotide analog reverse transcriptase inhibitor tenofovir. Pharmacogenomics, 2019; 20(2):105-111.
JIANG Y, et al. The Mechanisms of HBV-Induced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021; 8:435-450.
KIM JH, et al. Lamivudine versus Entecavir for Newly Diagnosed Hepatocellular Carcinoma. Gut and Liver, 2016; 10(9):939-947.
LI Q, et al. Interferon and interferon-stimulated genes in HBV treatment. Frontiers in Immunology, 2022; 13:1034968.
LI X, et al. Pharmacokinetics of tenofovir Alafenamide Fumarate and Tenofovir in the Chinese People: Effects of Non-Genetic Factors and Genetic Variations. Pharmacogenomics and Personalized Medicine, 2021; 14:1315-1329.
LIN F-C, YOUNG HA. Interferons: Success in anti-viral immunotherapy. Cytokines & Growth Factor Reviews, 2014; 25(4):369-376.
LOVETT GC, et al. Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience. World Journal of Hepatology, 2017; 9(1):48-56.
MACBRAYNE CE, et al. Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV - coinfected individuals receiving tenofovir disoproxil fumarate. Journal of Antimicrobial Chemotherapy, 2018; 73(8):2112-2119.
MERTOWSKA P, et al. Immunomodulatory Role of Interferon in Viral and Bacterial Infections. International Journal of Molecular, 2023; 24(12):10115.
MOHD-ISMAIL NK, et al. Mapping The Interactions of HBV cccDNA with Host Factors. International Journal of Molecular Sciences, 2019; 20(17):4276.
NEVOLA R, et al. HBV Infection and Host Interactions: The Role in Viral Persistent and Oncogenesis. International Journal of Molecular Sciences, 2023; 24(8):7651.
NOVOTNY LA, et al. Review of Lambda Interferon in Hepatitis B Virus Infection: Outcomes and Therapeutics Strategies. Viruses, 2021; 13(6):1090.
SCHOLLMEIR A, et al. Relevance of HBx for Hepatitis B Virus-Associated Pathogenesis. International Journal of Molecular Sciences, 2023; 24(5):4964.
SHORAKA S, et al. The role of hepatitis B virus genome variations in HBV-related HCC: effects on host signaling pathways. Frontiers in Microbiology, 2023; 14:1213145.
STADLER D, et al. Interferon-induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20. EMBO reports, 2021; 22(6): e49568.
TAKAMATSU Y, et al. 4’ -Modified Nucleoside Analogs: Potent Inhibitors Active against Entecavir-resistant Hepatitis B Virus. Hepatology, 2015; 62(4):1024-1036.
TAN G, et al. When Hepatitis B Virus Meets Interferons. Frontiers in Microbiology, 2018; 9:1611.
WANG S-H, et al. Unique Features of Hepatitis B Virus-Related Hepatocellular Carcinoma in Pathogenesis and Clinical Significance. Cancers, 2021; 13(10):2454.
WASSNER C, et al. A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide. Journal of the International Association of Provides of AIDS Care, 2020; 19:1-10.
WOO ASJ, et al. Alpha-interferon treatment in hepatitis B. Annals of Translational Medicine, 2017; 5(7):159.
XU F, et al. Type III interferon-induced CBFβ inhibits HBV replication by hijacking HBx. Cellular & Molecular Immunology, 2019; 16(4):357-366.
YANG M, XU X. Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs. Expert Opinion on Drug Metabolism & Toxicology, 2022; 18(7-8):483-505.
YASUTAKE Y, et al. HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir. Scientifics Reports, 2018; 8:1624.
YIN G-Q, et al. New Therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage. World Journal of Gastroenterology, 2021; 27(8):666-676.